sulfasalazine

E852342

anti-inflammatory drug azo compound disease-modifying antirheumatic drug pharmaceutical drug sulfonamide

Sulfasalazine is an anti-inflammatory drug commonly used to treat rheumatoid arthritis and inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (3)

Label	Occurrences
Azulfidine	1
Salazopyrin	1
sulfasalazine canonical	1

How this entity was disambiguated

This entity first appeared as the object of triple T10291881 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: sulfasalazine
Context triple: [BCRP, substrateOf, sulfasalazine]

A. methotrexate
Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain cancers by inhibiting folate-dependent cell proliferation.
B. Celebrex
Celebrex is a prescription nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation in conditions such as arthritis.
C. Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
D. Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
E. Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: sulfasalazine
Target entity description: Sulfasalazine is an anti-inflammatory drug commonly used to treat rheumatoid arthritis and inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.

A. methotrexate
Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain cancers by inhibiting folate-dependent cell proliferation.
B. Celebrex
Celebrex is a prescription nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation in conditions such as arthritis.
C. Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
D. Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
E. Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
F. None of above. chosen

Statements (61)

Predicate	Object
instanceOf	anti-inflammatory drug ⓘ azo compound ⓘ disease-modifying antirheumatic drug ⓘ pharmaceutical drug ⓘ sulfonamide ⓘ
hasATCCode	A07EC01 ⓘ M01CX01 ⓘ
hasBioavailability	poor ⓘ
hasCASNumber	599-79-1 ⓘ
hasCommonAdverseEffect	headache ⓘ loss of appetite ⓘ nausea ⓘ rash ⓘ vomiting ⓘ
hasComponent	5-aminosalicylic acid ⓘ sulfapyridine ⓘ
hasContraindication	porphyria ⓘ salicylate hypersensitivity ⓘ sulfonamide hypersensitivity ⓘ
hasEliminationHalfLife	5–10 hours ⓘ
hasExcretion	biliary ⓘ renal ⓘ
hasGenericName	sulfasalazine ⓘ
hasINN	sulfasalazine ⓘ
hasMechanismOfAction	acts as immunomodulator ⓘ inhibits NF-κB activation ⓘ inhibits prostaglandin synthesis ⓘ modulates inflammatory cytokine production ⓘ
hasMetabolism	colonic bacterial azo-reduction ⓘ hepatic acetylation ⓘ
hasMolarMass	398.39 g/mol ⓘ
hasMolecularFormula	C18H14N4O5S ⓘ
hasPregnancyCategoryUS	B (for inflammatory bowel disease) ⓘ B (for rheumatoid arthritis) ⓘ
hasProteinBinding	99% ⓘ
hasRouteOfAdministration	oral ⓘ
hasSeriousAdverseEffect	Stevens–Johnson syndrome ⓘ agranulocytosis ⓘ hemolytic anemia ⓘ hepatotoxicity ⓘ
hasTradeName	Azulfidine ⓘ linked to: sulfasalazine Salazopyrin ⓘ linked to: sulfasalazine
hasUSAN	sulfasalazine ⓘ
interactsWith	digoxin ⓘ folic acid ⓘ warfarin ⓘ
isAvailableAs	enteric-coated tablet ⓘ oral tablet ⓘ
isListedOn	WHO Model List of Essential Medicines ⓘ linked to: World Health Organization Model List of Essential Medicines
isProdrugOf	5-aminosalicylic acid ⓘ sulfapyridine ⓘ
mayCause	reversible oligospermia ⓘ
mayCauseDeficiencyOf	folate ⓘ
requiresMonitoring	complete blood count ⓘ liver function tests ⓘ
treats	Crohn’s disease ⓘ ankylosing spondylitis ⓘ juvenile idiopathic arthritis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ

How these facts were elicited

Referenced by (3)

Full triples — surface form annotated when it differs from this entity's canonical label.

BCRP → substrateOf → sulfasalazine ⓘ

sulfasalazine → hasTradeName → Azulfidine ⓘ

linked to: sulfasalazine

sulfasalazine → hasTradeName → Salazopyrin ⓘ